Please assess the completion status of the following clinical trial:

Trial Title: Treatment for COVID-19 in High-Risk Adult Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women 18 to 80 years of age, inclusive, at the time of signing the informed consent~* Willing and able to provide informed consent~* Laboratory confirmed SARS-CoV-2 infection, with test results within past 72 hours~* COVID-19 symptoms, based on the following criteria: At least TWO of the following symptoms: Fever (≥ 38ºC), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), OR o At least ONE of the following symptoms: cough, shortness of breath or difficulty breathing (Lopinavir-Ritonavir Platform)~* Access to device and internet for Telehealth visits~* At increased risk of developing severe COVID-19 disease (at least one of the following)~  1. Age ≥60 years~ 2. Presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema~ 3. Diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment~ 4. Hypertension, requiring at least 1 oral medication for treatment~ 5. Immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a CD4 T-cell count of \<200/mm3)~ 6. Immunocompromised status due to medication (e.g., persons taking 20 mg or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or cancer therapies)~ 7. Body mass index ≥30 (self-reported)~Exclusion Criteria:~* Known hypersensitivity to HCQ or other 4-aminoquinoline compounds~* Known hypersensitivity to azithromycin or other azalide or macrolide antibiotics~* Currently hospitalized~* Signs of respiratory distress prior to randomization, including respiratory rate \>24~* Current medications include HCQ~* Concomitant use of other anti-malarial treatment or chemoprophylaxis~* History of retinopathy of any etiology~* Psoriasis~* Porphyria~* Chronic kidney disease (Stage IV or receiving dialysis)~* Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes \<1500) or thrombocytopenia (\<100 K)~* Concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen~* Known cirrhosis~* Known personal or family history of long QT syndrome~* History of coronary artery disease with a history of graft or stent~* History of heart failure, Class 2 or greater using the New York Heart Association functional class~* Taking medications associated with prolonged QT and known risk of torsades de points. These medications may include some antipsychotic and antidepressant medications. (Lopinavir-Ritonavir Platform)~* Taking medications associated with prolonged QT such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial~* Taking warfarin (Coumadin or Jantoven)~* Known history of glucose-6-phosphate-dehydrogenase deficiency~* History of myasthenia gravis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Ascorbic acid and Folic acid (Type: PLACEBO_COMPARATOR): Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5)
- Hydroxychloroquine and Folic Acid (Type: EXPERIMENTAL): HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days \[Days 2 to 5\])
- Hydroxychloroquine and Azithromycin (Type: EXPERIMENTAL): HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5).
- Lopinavir-ritonavir (Type: EXPERIMENTAL): LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10)
- Ascorbic acid (Type: PLACEBO_COMPARATOR): Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy